Does adding ATG to the GVHD prophylaxis regimen help reduce its incidence? (multiple letters) [1]

Bone Marrow Transplantation

Volumn 31, Issue 4, 2003, Pages 311-313

  Ayas, M ^a   Al Mahr, Mohamad ^a   Al Jefri, Abdullah ^a   Rifai, Samira ^a   Solh, Hassan ^a   Bacigalupo, Andrea ^b  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; METHOTREXATE; PREDNISONE; THYMOCYTE ANTIBODY;

CLINICAL TRIAL; FANCONI ANEMIA; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; INFECTION RISK; LETTER; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTILYMPHOCYTE SERUM; FANCONI ANEMIA; GRAFT VS HOST DISEASE; HUMANS; INCIDENCE; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 0037297955     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703804     Document Type: Letter

References (0)